Research Highlights:
- A study of U.S. veterans identified 14 genes that may predict the risk of abdominal aortic aneurysm.
- The related-risk score identifies those at risk regardless of known factors such as smoking or family history.
- Diastolic blood pressure, the bottom number in a blood pressure reading, may be a better indicator of developing abdominal aortic aneurysm.
Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Sept. 28, 2020
DALLAS, Sept. 28, 2020 — A veteran’s study identified more than a dozen genes associated with abdominal aortic aneurysm (AAA) that could be used to better identify people at risk for the often-deadly condition, according to new research published today in the American Heart Association’s flagship journal Circulation.
Abdominal aortic aneurysm is a bulging or weakening of the aorta – the largest blood vessel in the body. Only about 20% of patients survive the rupture of an abdominal aortic aneurysm. Previous studies have detected 10 locations in the human genome associated with potential risks, however, those genes account for only a fraction of the causes for developing the condition.
“This study has doubled the number of genetic associations with abdominal aortic aneurysm, adding greatly to our understanding of the disease mechanisms,” said corresponding author Philip S. Tsao, Ph.D., a professor of cardiovascular medicine at Stanford University School of Medicine and director of the VA Palo Alto Epidemiology Research and Information Center for Genomics in California. “This new information can enhance screening protocols and help identify individuals at risk for abdominal aortic aneurysm.”
Researchers leveraged the world’s largest genetic biobank, The Million Veteran Program,
to pinpoint several new genetic factors associated with abdominal aortic aneurysm, as well as to identify new groups of people for future therapies. The Million Veteran Program was established in 2011 to study how genes affect the health of U.S. veterans.
Using the Million Veteran Program database, researchers performed a genome-wide association study in veterans of European ancestry, testing roughly 18 million DNA sequence variants among more than 7,500 abdominal aortic aneurysm cases and 172,000 veterans without abdominal aortic aneurysms.
They then examined the effects of blood pressure on abdominal aortic aneurysms using Mendelian randomization – a technique that leverages genetic variation to study the causal relationship between traits. They also studied whether abdominal aortic aneurysms risk factors were related to aneurysms in other areas of the body.
Throughout the testing, researchers created a “polygenic risk score” to help identify subsets of the population who are more likely to develop abdominal aortic aneurysms.
The analysis found:
- 14 previously unidentified genetic locations associated with abdominal aortic aneurysm development – bringing the total number of known gene associations to 24.
- A genetic increase of 10 mm Hg in diastolic blood pressure – the bottom number in a blood pressure reading – increased the risk of developing abdominal aortic aneurysm.
- 19 of the 24 risk variants for abdominal aortic aneurysm were associated with aneurysms in other parts of the body.
- The polygenic risk score was strongly associated with abdominal aortic aneurysm, regardless of known risk factors, including smoking and family history.
“We were surprised that diastolic blood pressure, as opposed to systolic blood pressure, is likely of greater significance in the development of abdominal aortic aneurysm,” Tsao said.
Researchers replicated the findings in an independent data set of nearly 5,000 abdominal aortic aneurysm cases and 100,000 controls (people who did not have abdominal aortic aneurysms).
Researchers say the study is somewhat limited since the database is primarily veterans of European ancestry. As the field of genetics advances, this suggests including more samples from people with diverse backgrounds to limit the possibility of ethnic disparities in precision medicine.
Co-authors are Derek Klarin, M.D.; Shefali Verma, Ph.D.; Renae Judy, M.S.; Ozan Dikilitas, M.D.; Brooke Wolford, B.S.; Ishan Paranjpe, B.S.; Michael Levin, M.D.; Cuiping Pan, Ph.D.; Catherine Tcheandjieu, Ph.D.; Joshua Spin, M.D., Ph.D.; Julie Lynch, Ph.D., R.N., M.B.A.; Themistocles Assimes, M.D., Ph.D.; Linn Nyronning, M.D.; Erney Mattsson, M.D.; Todd Edwards, Ph.D.; Joshua Denny, M.D., M.S.; Eric Larson, M.D.; Ming Ta Lee, Ph.D.; David Carrell, Ph.D.; Yanfei Zhang, M.D.; Gail Jarvik, M.D., Ph.D.; Ali Gharavi, M.D.; John Harley, M.D., Ph.D.; Frank Mentch, Ph.D.; Jennifer Pacheco, M.S.; Hakon Hakonarson, M.D.; Anne Skogholt, M.S.; Laurent Thomas, Ph.D.; Maiken Gabrielsen, Ph.D.; Kristian Hveem, M.D., Ph.D.; Jonas Nielsen, M.D., Ph.D.; Wei Zhou, Ph.D.; Lars Fritsche, Ph.D.; Jie Huang, M.D., Ph.D.; Pradeep Natarajan, M.D., M.M.Sc.; Yan Sun, Ph.D.; Scott DuVall, Ph.D.; Daniel Rader, M.D.; Kelly Cho, Ph.D.; Kyong-Mi Chang, M.D.; Peter Wilson, M.D.; Chris O’Donnell, M.D., M.P.H.; Sekar Kathiresan, M.D.; Salvatore Scali, M.D.; Scott Berceli, M.D., Ph.D.; Cristen Willer, Ph.D.; Gregory Jones, M.D.; Matthew Bown, M.D.; Girish Nadkarni, M.D.; Iftikhar Kullo, M.D.; Marylyn Ritchie, Ph.D.; and Scott Damrauer, M.D.
This study was funded by the U.S. Department of Veterans Affairs, the National Institutes of Health and grants from the National Human Genome Research Institute.
Additional Resources:
Statements and conclusions of studies published in the American Heart Association’s scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
###
For Media Inquiries and AHA Expert Perspective: 214-706-1173
Bridgette McNeill: bridgette.mcneill@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
Leave a Reply